Clinical Observation of Efficacy of Insulin Glargine Combined with Repaglinide to Type Ⅱ Diabetes

REN Xiang-dong
DOI: https://doi.org/10.3969/j.issn.1008-5971.2012.01.011
2012-01-01
Abstract:Objective To observe the clinical efficacy of insulin glargine combined with repaglinide to type 2 diabetes.Methods On the basis of the conventional treatment of diabetes,patients in control group were injected Novolin at 30R 0.3~1.0U·kg-1·d-1 30min before breakfast and dinner,while patients in observation group took 1mg repaglinide orally three times a day at first,and then the doses of repaglinide were adjusted every three days according to 2h postprandial blood glucose.The maximum dose of repaglinide was 4mg and three times a day.Insulin glargine were injected every night before bedtime at the starting dose of 0.1U·kg-1·d-1,and doses were individualized according to patients,condition.Fasting blood glucose,blood glucose 2h after breakfast and HbA1c were measured in both groups before and after treatment,and in the meantime,insulin dosage,body weight,BMI,the incidence of hypoglycemic events and safety indicators were observed.Results Comparing with control group,fasting blood glucose,blood glucose 2h after breakfast,insulin dosage,body weight,BMI and the incidence of hypoglycemic events were improved significantly in observation group.There were no obvious adverse events.Total effective rates between two groups had statistically significant difference(P<0.05).Conclusion The clinical efficacy of insulin glargine combined with repaglinide to type 2 diabetes is good and worthy to be popularized.
What problem does this paper attempt to address?